PlainPharmaWatch

CMS Open Payments · Program Year 2024

Avvisto Therapeutics, LLC

Avvisto Therapeutics, LLC reported $8,858.89 across General Payments, Research, and Ownership to 478 physicians and teaching hospitals across 478 transactions.

See the rankings → How this is sourced
$8.9K
All-tracks total
478
Transactions
478
Recipients
#1655
of 1,925 companies

Avvisto Therapeutics, LLC reported $8,858.89 across all CMS Open Payments tracks (General + Research + Ownership) to 478 physicians and teaching hospitals in Program Year 2024 - ranking #1655 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $8,858.89, averaging $18.53 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer avvisto-therapeutics-llc Avvisto Therapeutics, LLC

$8.9K · #1655/1,925 · 0.0% industry · PY2024

  • TOT $8.9K
  • RANK #1655
  • SHARE 0.0%
  • TXN 478
  • RCP 478
  • CAT 1
  • GEN $8.9K
  • TOP1 1.3%
  • PY 2024

Volume peers

Nearest volume peer: Auxano Medical LLC ($8.8K)

Biocartis US, Inc$9.2KDigestive Care, Inc.$9.0KAvvisto Therapeutics, LLC (t…$8.9KAuxano Medical LLC$8.8KProlaio, Inc.$8.5K
All-tracks payment totals near Avvisto Therapeutics, LLC (CMS Open Payments PY2024)

Avvisto Therapeutics, LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Avvisto Therapeutics, LLC

Rank #1655 of 1,925 companies in CMS Open Payments for 2024 belongs to Avvisto Therapeutics, LLC, which reported $8,858.89 across 478 transactions to 478 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $18.53 per transaction and $18.53 per recipient.

478 transactions worth $8.9K make "Food and Beverage" the top general-payment category in the 1-category breakdown below, 100.0% of General Payments (see our methodology for how research and ownership payments are reported separately).

General Payment Breakdown by Type

"Food and Beverage" leads Avvisto Therapeutics, LLC's 1-category general-payment breakdown at $8.9K, 100.0% of the reported total.

How Avvisto Therapeutics, LLC divides its payments

Top payment categories by total reported dollar volume

1. Food and Beverage$8.9K
Payment Type Amount Transactions
Food and Beverage $8.9K 478

Recipient Concentration in General Payments

The five largest recipient relationships account for $553.94 (6.3%) of $8,858.89 in this company's General Payments records across 297 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Avvisto Therapeutics, LLC

The five named recipients with the highest reported General Payments from this company

Laura S Dankovich$118.55David Walker$118.55Eric R Serrano$114.52Daryana Aronova$110.24Stella Ilyayeva$92.08
  1. 1

    Laura S Dankovich

    $118.55 across 2 reported transactions

  2. 2

    David Walker

    $118.55 across 2 reported transactions

  3. 3

    Eric R Serrano

    $114.52 across 3 reported transactions

  4. 4

    Daryana Aronova

    $110.24 across 6 reported transactions

  5. 5

    Stella Ilyayeva

    $92.08 across 5 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Avvisto Therapeutics, LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Avvisto Therapeutics, LLC.

Electronic Waveform Lab, Inc.

HHI 47

Neurocrine Biosciences, Inc.

HHI 47

W. L. Gore & Associates, Inc.

HHI 47

Aucta Pharmaceuticals, Inc.

HHI 46

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Avvisto Therapeutics, LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Avvisto Therapeutics, LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.